In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Michel Komajda
Speaker
Michel Komajda
Michel Komajda Michel Komajda

Groupe Hospitalier Paris Saint-Joseph, Paris (France)

Specialities : Acute Heart Failure , Chronic Heart Failure, Myocardial Disease

Michel Komajda is a Past President of the European Society of Cardiology and of the French Cardiac Society.He was also chairperson of the congress programme committee ESC 2005-2006 and of the Global scientific Affairs (2010-2014). He is an expert in heart failure management and chaired the working group on heart failure of the ESC, Euro Survey I and was a member of the writting committee of guidelines on the management of heart failure on two occasions. he has been member of the steering committee, of the clinical endpont committee or DSMB of many heart failure clinical trials including SHIFT, CORONA, I PRESERVE, COMET, PARADIGM HF, CARMEN, EMPHESUS, RENAISSANCE, PARAGON. He created the cardio genetic department in his university hosptial Pitie Salpetriere He received the Heart Failure Association life time award in 2017. He has written # 250 peer review articles in the highest profile peer review international journals.

47 presentations from this speaker

Betablockers/ivabradine

Event : Heart Failure 2019

  • Session : Chronic heart failure: optimising patient management
  • Speaker : M Komajda (Paris,FR)

ESC Asia with APSC & AFC Awards and Closing Remarks

Event : ESC Asia 2019

  • Session : Closing Session
  • Speaker : M Komajda (Paris,FR), K Yeo (Singapore,SG)

Heart Failure.

Event : ESC Asia 2019

  • Session : Highlights of ESC Congress 2019 - II
  • Speaker : M Komajda (Paris,FR)

How to treat Heart Failure with Preserved Ejection Fraction.

Event : ESC Asia 2019

  • Session : All I Should Know about Heart Failure with Preserved Ejection Fraction
  • Speaker : M Komajda (Paris,FR)

Introduction

Event : ESC Asia 2019

  • Session : The burden of cardiovascular diseases in 2020: from angina treatment to optimized care of heart failure
  • Speaker : M Komajda (Paris,FR)
  • Sponsored by Servier

Keynote Lecture: Heart Failure and Diabetes.

Event : ESC Asia 2019

  • Session : Opening Session
  • Speaker : M Komajda (Paris,FR)

The Chronic ischemic cardio vascular disease registry(CICD) baseline characteristics.

Event : ESC Congress 2019

  • Session : EORP registry symposium
  • Speaker : M Komajda (Paris,FR)

Welcome.

Event : ESC Asia 2019

  • Session : Opening Session
  • Speaker : M Komajda (Paris,FR), K Yeo (Singapore,SG)

What we learnt from registries about heart failure therapy implementation

Event : ESC Congress 2019

  • Session : Expert Advice - Optimising the organisation of heart failure care
  • Speaker : M Komajda (Paris,FR)

Diabetes mellitus and insulin resistance

Event : Heart Failure 2018

  • Session : Prevention remains the best treatment in heart failure
  • Speaker : M Komajda (Paris,FR)

Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis

Event : Heart Failure 2018

  • Session : Late breaking trial II - Chronic heart failure
  • Speaker : M Komajda (Paris,FR)

Introduction - Optimizing heart failure treatments before discharge.

Event : Heart Failure 2018

  • Session : Optimizing heart failure treatments before discharge
  • Speaker : M Komajda (Paris,FR)
  • Sponsored by SERVIER

A snapshot of today’s heart failure patients.

Event : ESC Congress 2017

  • Session : When to optimize heart failure treatment?
  • Speaker : M Komajda (Paris,FR)
  • Sponsored by SERVIER

Coronary artery disease: CICD Pilot registry 6 month follow-up.

Event : ESC Congress 2017

  • Session : Valuable lessons on frequent diseases - Insights from ESC registries
  • Speaker : M Komajda (Paris,FR)
  • Joint with the EURObservation Research Programme (EORP)

Discussion - When to optimize heart failure treatment ?

Event : ESC Congress 2017

  • Session : When to optimize heart failure treatment?
  • Speaker : S Anker (Berlin,DE), M Boehm (Homburg,DE), M Cowie (London,GB), M Komajda (Paris,FR), Y Lopatin (Volgograd,RU)
  • Sponsored by SERVIER

Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomised placebo-controlled trial.

Event : Heart Failure 2017

  • Session : Late Breaking Trials II: Focus on chronic heart failure
  • Speaker : M Komajda (Paris,FR)

Introduction.

Event : Heart Failure 2017

  • Session : Journey of a heart failure patient: similarities and differences across the world
  • Speaker : M Komajda (Paris,FR)
  • Sponsored by SERVIER

Panel discussion - Managing heart failure in 2017.

Event : ESC Congress 2017

  • Session : Managing heart failure in 2017: the experts’ opinion
  • Speaker : M Komajda (Paris,FR), JJV McMurray (Glasgow,GB), D Atar (Oslo,NO), F Ruschitzka (Zurich,CH)
  • Organised by Medscape Education, supported with an educational grant by Novartis

Panel discussion and conclusion - On the cutting edge of heart failure management: 2017.

Event : ESC Congress 2017

  • Session : On the cutting edge of heart failure management: 2017
  • Speaker : M Komajda (Paris,FR)
  • Organised by Medscape Education, supported with an educational grant by Novartis

The chronic ischemic cardiovascular disease (CICD) ESC Pilot Registry: results of the six months follow-up

Event : ESC Congress 2017

  • Session : Late-Breaking ESC Registry Results
  • Speaker : M Komajda (Paris,FR)

Welcome & introduction - On the cutting edge of heart failure management: 2017.

Event : ESC Congress 2017

  • Session : On the cutting edge of heart failure management: 2017
  • Speaker : M Komajda (Paris,FR)
  • Organised by Medscape Education, supported with an educational grant by Novartis

Conclusion.

Event : Heart Failure 2016

  • Session : Optimizing heart failure care: if not now, when?
  • Speaker : M Komajda (Paris,FR)
  • Sponsored by SERVIER

Diabetes.

Event : Heart Failure 2016

  • Session : Drug therapy in the patient with comorbidities
  • Speaker : M Komajda (Paris,FR)

Ivabradine reduces early readmission after hospitalization for worsening heart failure: a post-hoc analysis of SHIFT

Event : Heart Failure 2016

  • Session : Clinical Forum - Sat. 21 May 08:30 - Sun. 22 May 18:00
  • Speaker : M Komajda (Paris,FR)

MORE-CARE - Discussant review.

Event : ESC Congress 2016

  • Session : Hot Line heart failure and innovative approaches
  • Speaker : M Komajda (Paris,FR)

Neurohormonal antagonists.

Event : Heart Failure 2016

  • Session : Individualising therapy in heart failure
  • Speaker : M Komajda (Paris,FR)

A case of chronic heart failure with high heart rate.

Event : ESC Congress 2015

  • Session : Heart failure
  • Speaker : M Komajda (Paris,FR)

A case of HFpEF with EF 45% and its treatment - What do the Guidelines say?

Event : ESC Congress 2015

  • Session : Heart failure
  • Speaker : M Komajda (Paris,FR)

Antidiabetic drugs: a burnt concept in heart failure therapy?

Event : Heart Failure 2015

  • Session : Metabolic targets in heart failure
  • Speaker : M Komajda (Paris,FR)

Conclusion.

Event : Heart Failure 2015

  • Session : Preventing heart failure rehospitalization: a collaborative effort
  • Speaker : M Komajda (Paris,FR)
  • Sponsored by SERVIER

CUPID 2: Discussant review.

Event : ESC Congress 2015

  • Session : Hot Line V- Heart failure
  • Speaker : M Komajda (Paris,FR)

Introduction - Restoring hope to heart failure patients.

Event : ESC Congress 2015

  • Session : Restoring hope to heart failure patients
  • Speaker : M Komajda (Paris,FR)
  • Organised by Universitatsklinikum Des Saarlandes Course Director: Michael Boehm Supported by an unrestricted educational grant from SERVIER

Let’s decide together how to prevent rehospitalization.

Event : Heart Failure 2015

  • Session : Preventing heart failure rehospitalization: a collaborative effort
  • Speaker : M Cowie (London,GB), A Voors (Groningen,NL), M Komajda (Paris,FR), M Boehm (Homburg,DE), JS Borer (New York,US)
  • Sponsored by SERVIER

Physician's adherence to evidence-based pharmacotherapy in systolic heart failure: data from international QUALIFY survey

Event : Heart Failure 2015

  • Session : Late Breaking Trials II: Heart failure management
  • Speaker : M Komajda (Paris,FR)

Is treatment of diabetes different in heart failure?

Event : ESC Congress 2014

  • Session : Diabetes and heart failure: liaisons dangereuses
  • Speaker : M Komajda (Paris,FR)

Ordinary General Assembly. Results of the ESC elections

Event : ESC Congress 2014

  • Session : ESC General Assemblies
  • Speaker : M Komajda (Paris,FR)

Panel.

Event : ESC Congress 2014

  • Session : PARADIGM-HF: The experts' discussion
  • Speaker : JJV McMurray (Glasgow,GB), M Packer (Dallas,US), K Fox (Edinburgh,GB), M Komajda (Paris,FR)

PARADIGM-HF: Discussant review

Event : ESC Congress 2014

  • Session : Hot Line: Cardiovascular disease: novel therapies
  • Speaker : M Komajda (Paris,FR)

Presentation of the awardee.

Event : ESC Congress 2014

  • Session : ESC Geoffrey Rose Lecture on Population Sciences
  • Speaker : M Komajda (Paris,FR)

Why did trials fail?

Event : ESC Congress 2014

  • Session : Challenges in heart failure with preserved ejection fraction
  • Speaker : M Komajda (Paris,FR)

Heart rate modulators.

Event : ESC Congress 2013

  • Session : Treatment of chronic heart failure: update 2013
  • Speaker : M Komajda (Paris,FR)

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are